Skip to main content

World Ovarian Cancer Day 2024

New Content ItemFollowing cervical and uterine cancer, ovarian cancer (OC) ranks third in gynecologic cancers for frequency but has the highest rate of death. A woman’s risk of getting ovarian cancer during her lifetime is about 1 in 78, with a mortality rate of around 1 in 108. OC often remains non-diagnosed until it spreads throughout the pelvis and abdomen, making treatment difficult.

For World Ovarian Cancer Day 2024, we'd like to highlight some of our most impactful research and review articles on OC in the last few years, which have extensively contributed to the field.

We'd like to congratulate our authors on this achievement, which cements Journal of Ovarian Research as a top destination for OC content.

For our 2023 highlights, please see here and for more information on WOCD from the World Ovarian Cancer Coalition including how to get involved, please see here.

Featured Q&As

New Content Item

We spoke to Dr Trevor Shepherd about his research on ovarian cancer, particularly the numerous molecular, cellular, and biochemical changes that occur in ovarian cancer spheroids. The Shepherd Lab are seeking to determine whether key signaling pathways and processes that are activated in spheroids represent new therapeutic vulnerabilities in the context of metastatic disease in the hopes of enhancing personalized medicine for cancer patients.

Read the Q&A here.

New Content Item

Dr Meshach Asare-Werehene is currently investigating the immuno-suppressive role of plasma gelsolin, a biomarker for ovarian cancer, in chemoresistant ovarian cancer. Chemo-resistant ovarian cancer cells produce large amounts of plasma gelsolin, which prevents cancer-killing immune cells from doing their job. Chemotherapy may work better if plasma gelsolin is blocked. We spoke with him on what fueled his passion to join the field and what he hopes to see in the future of ovarian cancer treatment.

Read the Q&A here.

Featured Articles

Stearoyl-CoA desaturase 1 inhibition induces ER stress-mediated apoptosis in ovarian cancer cells
Juwon Lee, Suin Jang, Jihye Im, Youngjin Han, Soochi Kim, HyunA Jo, Wenyu Wang, Untack Cho, Se Ik Kim, Aeran Seol, Boyun Kim & Yong Sang Song  
Research  |   Published: 02 April 2024

Sialyl-Tn serves as a potential therapeutic target for ovarian cancer
Linah Al-Alem, Jillian M. Prendergast, Justin Clark, Bianca Zarrella, Dominique T. Zarrella, Sarah J. Hill, Whitfield B. Growdon, Venkatesh Pooladanda, David R. Spriggs, Daniel Cramer, Kevin M. Elias, Rawan I. Nazer, Steven J. Skates, Jeff Behrens, Daniel T. Dransfield & Bo R. Rueda 
Research  |   Published: 02 April 2024

PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials
István Baradács, Brigitta Teutsch, Alex Váradi, Alexandra Bilá, Ádám Vincze, Péter Hegyi, Tamás Fazekas, Balázs Komoróczy, Péter Nyirády, Nándor Ács, Ferenc Bánhidy & Balázs Lintner   
Review  |   Published: 26 February 2024

From clinical management to personalized medicine: novel therapeutic approaches for ovarian clear cell cancer
Zesi Liu, Chunli Jing & Fandou Kong  
Review |   Published: 12 February 2024

The regulation of plasma gelsolin by DNA methylation in ovarian cancer chemo-resistance
Hafiza Bushra Manzoor, Meshach Asare-Werehene, Satyajit Dey Pereira, Kapaettu Satyamoorthy & Benjamin K. Tsang 
Research  |   Published: 12 January 2024

A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer
Jiani Yang, Chao Wang, Yue Zhang, Shanshan Cheng, Yanna Xu & Yu Wang  
Research  |   Published: 20 September 2023

A methylation- and immune-related lncRNA signature to predict ovarian cancer outcome and uncover mechanisms of chemoresistance
Lu Chen, Wujiang Gao, Li Lin, Chunli Sha, Taoqiong Li, Qi Chen, Hong Wei, Meiling Yang, Jie Xing, Mengxue Zhang, Shijie Zhao, Wenlin Xu, Yuefeng Li, Lulu Long & Xiaolan Zhu 
Research  |   Published: 06 September 2023

The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial
Youwen Zhu, Kun Liu, Hui Cao & Hong Zhu 
Research  |   Published: 21 August 2023

Genomic analyses of germline and somatic variation in high-grade serous ovarian cancer
A. W. Adamson, Y. C. Ding, L. Steele, L. A. Leong, R. Morgan, M. T. Wakabayashi, E. S. Han, T. H. Dellinger, P. S. Lin, A. A. Hakim, S. Wilczynski, C. D. Warden, S. Tao, V. Bedell, M. C. Cristea & S. L. Neuhausen 
Research  |   Published: 17 July 2023

Trends in incidence and mortality for ovarian cancer in China from 1990 to 2019 and its forecasted levels in 30 years
Jianyang Feng, Lijiang Xu, Yangping Chen, Rongjin Lin, Haoxian Li & Hong He 
Research  |   Published: 14 July 2023

LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer
Goutam Dey, Rashmi Bharti, Chad Braley, Ravi Alluri, Emily Esakov, Katie Crean-Tate, Keith McCrae, Amy Joehlin-Price, Peter G. Rose, Justin Lathia, Zihua Gong & Ofer Reizes 
Research  |   Published: 27 June 2023

SPON1 is an independent prognostic biomarker for ovarian cancer
Ryoya Miyakawa, Makoto Kobayashi, Kotaro Sugimoto, Yuta Endo, Manabu Kojima, Yasuyuki Kobayashi, Shigenori Furukawa, Tsuyoshi Honda, Takafumi Watanabe, Shigeyuki Asano, Shu Soeda, Yuko Hashimoto, Keiya Fujimori & Hideki Chiba 
Research  |   Published: 13 May 2023

Annual Journal Metrics

  • 2022 Citation Impact
    4.0 - 2-year Impact Factor
    4.7 - 5-year Impact Factor
    1.118 - SNIP (Source Normalized Impact per Paper)
    0.965 - SJR (SCImago Journal Rank)

    2023 Speed
    10 days submission to first editorial decision for all manuscripts (Median)
    138 days submission to accept (Median)

    2023 Usage 
    475 Altmetric mentions